| 摘要: |
| 目的：观察复方菝葜颗粒治疗晚期非小细胞肺癌的临床疗效。方法：将60例晚期非小细胞肺癌患者随机分为2组，每组各30例。对照组予以化疗药物治疗，治疗组在化疗药物治疗基础上，从化疗第1天开始服用复方拔葜颗粒。2组均治疗2个周期后对其主要症状与生活质量（KPS评分）改善情况及1年生存率进行比较。结果：2组主要症状改善总有效率治疗组为86.67%，对照组为56.67%；生活质量改善总稳定率治疗组为83.33%，对照组为56.67%；1年生存率治疗组为83.33%，对照组为60.00%；组间比较，差异均有统计学意义（P<0.05）。结论：复方菝葜颗粒治疗晚期非小细胞肺癌有一定临床价值。 |
| 关键词: 非小细胞肺癌 中西医结合疗法 复方菝葜颗粒 |
| DOI： |
|
|
| Clinical efficacy of compound Baqia granules in treatment of advanced non-small cell lung cancer：An analysis of 30 cases |
| YIN Tianlei，,ZHU Lihua，,XIAO Juan， |
| (Hunan Academy of Chinese Medicine，Changsha 410006，Hunan，China) |
| Abstract: |
| Objective：To investigate the clinical efficacy of compound Baqia granules in the treatment of advanced non-small cell lung cancer（NSCLC).Methods：A total of 60 patients with advanced NSCLC were equally and randomly divided into control group and treatment group.The control group was given chemotherapeutic drugs，while the treatment group was given compound Baqia granules from the first day of chemotherapy in addition to the chemotherapeutic drugs.After two courses of treatment，the improvements in main symptoms and quality of life（Karnofsky Performance Scale score) and 1-year survival rate were compared between the two groups.Results：There were significant differences in the overall rate of improvement in main symptoms（86.67% vs 56.67%，P<0.05)，overall stability rate of improvement in quality of life（83.33% vs 56.67%，P<0.05)，and 1-year survival rate（83.33% vs 60.00%，P<0.05) between the treatment group and the control group.Conclusion：Compound Baqia granules have good clinical efficacy in the treatment of advance NSCLC. |
| Key words: non-small cell lung cancer integrated traditional Chinese and Western medicine therapy compound Baqia granule |
